The 2011 World Drug Safety Congress begins today (September 13) in London, UK.
The congress, which runs until Friday September 16, will feature talks from a range of industry experts, including representatives from Baxter Healthcare, Otsuka Pharmaceutical Development & Commercialisation, Bayer Vital, F.Hoffmann-La Roche and Pfizer.
Speaking ahead of the congress, Dr Micheal Forstner, Safety Risk Manager at F.Hoffmann-La Roche, was asked what key trends he expected to see in the drug safety industry over the next five years.
“There will be a move from Risk to Benefit-Risk management, which will require closer collaboration and mutual understanding between Clinical sciences, Drug safety, and Med Affairs,” he said.
“There will be more cross-functional collaboration with pharma outcomes and business functions to introduce new methodology to safety.
“ENCePP [the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance] will require a more transparent approach to safety, and other regions will probably follow that model.”
Dr Forstner will be discussing how to maximise the benefit and minimise risk as part of this afternoon’s programme.
Other topics include:
• Emerging Market Focus
• International Regulatory Roundup
• Risk Management & Communication
• Benefit Risk Decision Making
• Signal Reporting & Management
• Clinical Safety Strategy
• Safety in Early Development
• Observational Studies/Post Approval Safety